UCLA licensed out this life-extending drug to Medivation Inc., which was partnered with Astellas, in 2005. Pfizer obtained Medivation in 2016 after UCLA sold its royalty rights for $520 million and now holds the patent with Astellas. UCLA then continued to fight the battle for Big Pharma in India to prevent the distribution of generic versions, which were being sold at much lower prices. Outraged, members of Universities Allied for Essential Medicines at UCLA organized student protests, reached out to administrators and collected signatures to address this injustice.